Crown Laboratories, Inc., an integrated skin care company, has acquired North American distribution rights to five OTC consumer brands from GlaxoSmithKline.
The products expand Crown Laboratories’ consumer portfolio by adding brands that treat multiple conditions. The acquired portfolio includes:
- PanOxyl daily acne wash
- Sarna anti-itch lotion
- Zeasorb anti-fungal and prevention product
- Desenex anti-fungal powder for athlete’s foot
- Mineral Ice pain-relieving gel
PanOxyl, Sarna, and Zeasorb are former Stiefel Laboratories, Inc. brands. “Acquiring these strong heritage brands strengthens Crown’s OTC portfolio and adds significant value across multiple categories,” said Jeff Bedard, Crown Laboratories President and CEO.
Crown Laboratories has chosen the Emerson Group to manage the sales activity and all logistics for the PanOxyl, Sarna, Zeasorb, Desenex, and Mineral Ice brands across all retailers.
Financial terms of the transaction were not disclosed.
(Sources: Crown Laboratories, Inc. and Business Wire)
